Skip to main content

Table 11 Other reported adverse events

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

Condition Observations Treatment
Hypertension 1 UP446 250 mg
Varicose veins 1 UP446 250 mg
Fluid in knee 1 UP446 250 mg
Reduced flexibility 1 Placebo
Psoriasis 2 UP446 250 and 500 mg